Abstract: This disclosure relates to targeted protease compositions and uses related thereto. In certain embodiments, the disclosure relates to nanoparticles wherein a targeting molecule is linked to the nanoparticle and wherein a catalytic domain of a protease is linked to the nanoparticle. In certain embodiments, the targeting molecule and the catalytic domain are within a single polypeptide sequence. In certain embodiments, the targeting molecule binds a molecule more highly expressed on cancer cells then non-cancerous cells, and the nanoparticles disclosed herein are used for the treatment of cancer by further attaching an anti-cancer agent to the nanoparticle or incorporating an anticancer agent within the nanoparticle.

Abstract: This disclosure relates to palladium hyaluronic acid particles such as dibenzylideneacetone palladium hyaluronic acid particles. In certain embodiments, this disclosure relates to methods of managing cancer or angiogenic conditions using particles disclosed herein and pharmaceutical compositions comprising the same. In certain embodiments, an objective of this disclosure is hyaluronic acid targeting of CD44, a tumor stem cell marker. In certain embodiments, this disclosure relates to treatment with hyaluronic acid palladium particles disclosed herein for depleting CD44 cells.

Abstract: This disclosure relates to targeted protease compositions and uses related thereto. In certain embodiments, the disclosure relates to nanoparticles wherein a targeting molecule is linked to the nanoparticle and wherein a catalytic domain of a protease is linked to the nanoparticle. In certain embodiments, the targeting molecule and the catalytic domain are within a single polypeptide sequence. In certain embodiments, the targeting molecule binds a molecule more highly expressed on cancer cells then non-cancerous cells, and the nanoparticles disclosed herein are used for the treatment of cancer by further attaching an anti-cancer agent to the nanoparticle or incorporating an anticancer agent within the nanoparticle.

Abstract: Disclosed herein are invariant natural killer T (iNKT) cells engineered using hematopoietic stem and progenitor cells (HSPCs) and methods of making and using thereof.

Abstract: This disclosure relates to peptides and nanoparticles comprising a surface molecule that binds or blocks PD-L1. In certain embodiments, the disclosure relates to methods of using peptides or nanoparticles disclosed herein for the treatment of cancer. In certain embodiments, the disclosure relates to methods of using nanoparticles disclosed herein for therapeutic and diagnostic applications.

Abstract: The invention relates to a method for forming flip chip bumps using electroplating. The method allows the formation of flip chip bumps in a way that is compatible with already-formed sensitive electronic components, such as Josephson junctions, which may be used in quantum processing units. The invention also relates to a product and a flip chip package in which flip chip bumps are formed with the disclosed method.

Abstract: A magnetic resonance imaging (MRI) system and method integrating multi-nuclide synchronous imaging and spectral imaging is provided. The MRI system includes a spectral imaging module, a multi-nuclide synchronous imaging module, and a spectral reconstruction and image fusion module, where the spectral imaging module is configured to acquire a spectrum of a nuclide Nuc; the multi-nuclide synchronous imaging module is configured to perform synchronous imaging of nuclides Nuc1 . . . Nucn, where when n=1, Nucl is 1H; and when n>1, Nucn is a non-1H nuclide; and the spectral reconstruction and image fusion module is configured to receive the spectrum of the nuclide Nuc and images of the nuclides Nuc1 . . . Nucn, and acquire spatial distribution information of compounds of the nuclide Nuc and spatial distribution information of the non-1H nuclide through fusion. The system and method can synchronously acquire MR signals of different nuclides, and reconstruct and fuse non-1H nuclide images.

Abstract: A system and method for authenticating users of a data processing platform stores a mapping of a unique user platform identifier to multiple user identity provider identifiers associated with multiple realms for a same user. In some examples, the method includes receiving a request from a client device to establish an access session to perform one or more actions on data of the data processing platform and receiving, from at least one of the first external identity provider of the first realm or the second external identity provider of the second realm, a user identity provider identifier associated with the request. In certain examples, the method includes granting permission to perform the one or more actions on the data of the data processing platform based at least in part on the received user identity provider identifier.

Abstract: This disclosure relates to peptides and nanoparticles comprising a surface molecule that binds or blocks PD-L1. In certain embodiments, the disclosure relates to methods of using peptides or nanoparticles disclosed herein for the treatment of cancer. In certain embodiments, the disclosure relates to methods of using nanoparticles disclosed herein for therapeutic and diagnostic applications.

Abstract: A magnetic resonance imaging (MRI) system and method integrating multi-nuclide synchronous imaging and spectral imaging is provided. The MRI system includes a spectral imaging module, a multi-nuclide synchronous imaging module, and a spectral reconstruction and image fusion module, where the spectral imaging module is configured to acquire a spectrum of a nuclide Nuc; the multi-nuclide synchronous imaging module is configured to perform synchronous imaging of nuclides Nuc1 . . . . Nucn, where when n=1, Nucl is 1H; and when n>1, Nucn is a non-1H nuclide; and the spectral reconstruction and image fusion module is configured to receive the spectrum of the nuclide Nuc and images of the nuclides Nuc1 . . . . Nucn, and acquire spatial distribution information of compounds of the nuclide Nuc and spatial distribution information of the non-1H nuclide through fusion. The system and method can synchronously acquire MR signals of different nuclides, and reconstruct and fuse non-1H nuclide images.

Abstract: The invention relates to the field of oilfield chemistry, and discloses a self-repairing plugging gel polymer for drilling fluid, a preparation method and application thereof, and the drilling fluid containing the gel polymer, wherein the polymer contains a structural unit A, a structural unit B, a structural unit C and a structural unit D, and the structural unit A is a structural unit with a structure shown in the formula (1); the structural unit B is a structural unit with a structure shown in the formula (2); the structural unit C is a structural unit with a structure shown in the formula (3); the structural unit D is a structural unit having a structure represented by the formula (4).

Abstract: A lifting device for building a steel structure hoistway and a method for building a steel structure hoistway. The lifting device includes a lifting mechanism and a crane mechanism. The lifting mechanism includes a bottom platform, a middle platform and a top platform. The crane mechanism is arranged on the top platform of the lifting mechanism, and includes a base and a crane on the base. The base is arranged on the top platform and is rotatable relative to the top platform along a vertical axis, and the hanger frame of the crane is movable between a vertical orientation and an inclined orientation. The lifting mechanism is configured to ascend and descend in the constructed steel structure hoistway, and the crane mechanism is configured to lift building materials, such as steel beams, steel columns, etc., for use in building the steel structure hoistway to their designed installation locations.

Abstract: A system and method for authenticating users of a data processing platform stores a mapping of a unique user platform identifier to multiple user identity provider identifiers associated with multiple realms for a same user. In some examples, the method includes receiving a request from a client device to establish an access session to perform one or more actions on data of the data processing platform and receiving, from at least one of the first external identity provider of the first realm or the second external identity provider of the second realm, a user identity provider identifier associated with the request. In certain examples, the method includes granting permission to perform the one or more actions on the data of the data processing platform based at least in part on the received user identity provider identifier.

Abstract: A lifting device for building a steel structure hoistway and a method for building a steel structure hoistway. The lifting device includes a lifting mechanism and a crane mechanism. The lifting mechanism includes a bottom platform, a middle platform and a top platform. The crane mechanism is arranged on the top platform of the lifting mechanism, and includes a base and a crane on the base. The base is arranged on the top platform and is rotatable relative to the top platform along a vertical axis, and the hanger frame of the crane is movable between a vertical orientation and an inclined orientation. The lifting mechanism is configured to ascend and descend in the constructed steel structure hoistway, and the crane mechanism is configured to lift building materials, such as steel beams, steel columns, etc., for use in building the steel structure hoistway to their designed installation locations.

Abstract: Methods, apparatus, systems, and articles of manufacture are disclosed to detect attacks in V2X networks. An example apparatus includes a challenge handler to (a) transmit a first challenge packet to a first vehicle to request a transmission of a first response, (b) instruct a second challenge packet to be transmitted to a second vehicle to request a transmission of a second response, (c) increment a first counter when the first response is not obtained, (d) increment a second counter when the second response is not obtained, and (e) after repeating (a)-(d), determine that the first and second vehicles are phantom vehicles associated with an attacker with a half-duplex radio when at least one of the first or second counters satisfy a threshold, and a network interface to instruct a third vehicle associated with the V2X network to ignore future messages from the phantom vehicles based on the determination.

Abstract: Systems and methods generate a first security node hash identifier by performing a first hash operation, such as a one-way hash, on a first data resource identifier associated with a first data resource, such as a data set, produced by a data resource platform. The systems and methods generate a dependent second security node hash identifier by performing a second hash operation on a second data resource identifier associated with a dependent second data resource produced by the data resource platform and on the first security node hash identifier, receive an access request for access to the dependent second data resource; and in response to the access request, grant permission to access the dependent second data resource to a user associated with the access request based on the dependent second security node hash identifier.

Abstract: A first roadway system receives a communication from a second roadway system over a wireless channel, where the communication includes a description of a physical object within a driving environment. Characteristics of the physical object are determined based on sensors of the first roadway system. The communication is determined to contain an anomaly based on a comparison of the description of the physical object with the characteristics determined based on the sensors of the first roadway system. Misbehavior data is generated to describe the anomaly. A remedial action is initiated based on the anomaly.

Abstract: This disclosure relates to targeted protease compositions and uses related thereto. In certain embodiments, the disclosure relates to nanoparticles wherein a targeting molecule is linked to the nanoparticle and wherein a catalytic domain of a protease is linked to the nanoparticle. In certain embodiments, the targeting molecule and the catalytic domain are within a single polypeptide sequence. In certain embodiments, the targeting molecule binds a molecule more highly expressed on cancer cells then non-cancerous cells, and the nanoparticles disclosed herein are used for the treatment of cancer by further attaching an anti-cancer agent to the nanoparticle or incorporating an anticancer agent within the nanoparticle.

Abstract: We have discovered MAO-A induction in mouse and human TAMs. Moreover, we determined that MAO-A-deficient mice exhibited decreased TAM immunosuppressive functions corresponding with enhanced antitumour immunity. Building upon these discoveries, we then determined that MAOI treatment induced TAM reprogramming and suppressed tumour growth in preclinical mouse syngeneic and human xenograft tumour models. Surprisingly, combining MAOI and anti-PD-1 treatments resulted in synergistic tumour suppression. Together, these data identify MAO-A as a critical regulator of TAMs, and that show that repurposing MAOIs for TAM reprogramming can be used to improve cancer immunotherapies.

Abstract: Monoamine oxidase A (MAO-A) is an enzyme best known for its function in the brain, where it breaks down neurotransmitters and thereby influences mood and behavior. While small molecule MAO inhibitors (MAOIs) have been developed used for treating depression and other neurological disorder, the involvement of MAO-A in antitumor immunity has not been known. The disclosure provided herein identifies MAO-A as an immune checkpoint and the use of MAOI antidepressants for cancer immunotherapy. Here we report induction of the Maoa gene in tumor-infiltrating immune cells. MAOI treatment significantly suppressed tumor growth in preclinical mouse syngeneic and human xenograft tumor models in a T cell-dependent manner. Combining MAOI and anti-PD-1 treatments generated synergistic tumor suppression effects. Clinical data correlation studies associated intratumoral MAOA expression with T cell dysfunction and impaired patient survival in a broad range of cancers.